1292 related articles for article (PubMed ID: 28027313)
21. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
[TBL] [Abstract][Full Text] [Related]
22. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
23. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
24. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
26. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
[TBL] [Abstract][Full Text] [Related]
27. Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.
He J; Tan W; Tang X; Ma J
Pathol Oncol Res; 2017 Apr; 23(2):307-315. PubMed ID: 27511219
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Fan G; Zhang K; Ding J; Li J
Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611
[TBL] [Abstract][Full Text] [Related]
29. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
[TBL] [Abstract][Full Text] [Related]
30. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
[TBL] [Abstract][Full Text] [Related]
32. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
[TBL] [Abstract][Full Text] [Related]
33. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
34. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
35. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.
Chen S; Zhao J; Cui L; Liu Y
Clin Transl Oncol; 2017 Mar; 19(3):332-340. PubMed ID: 27468867
[TBL] [Abstract][Full Text] [Related]
36. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.
Phallen J; Leal A; Woodward BD; Forde PM; Naidoo J; Marrone KA; Brahmer JR; Fiksel J; Medina JE; Cristiano S; Palsgrove DN; Gocke CD; Bruhm DC; Keshavarzian P; Adleff V; Weihe E; Anagnostou V; Scharpf RB; Velculescu VE; Husain H
Cancer Res; 2019 Mar; 79(6):1204-1213. PubMed ID: 30573519
[TBL] [Abstract][Full Text] [Related]
37. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer.
Wan R; Wang Z; Lee JJ; Wang S; Li Q; Tang F; Wang J; Sun Y; Bai H; Wang D; Zhao J; Duan J; Zhuo M; An T; Wu M; Chen Z; Yang Z; Wang J
J Thorac Oncol; 2017 Sep; 12(9):1376-1387. PubMed ID: 28552765
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.
Qiu M; Wang J; Xu Y; Ding X; Li M; Jiang F; Xu L; Yin R
Cancer Epidemiol Biomarkers Prev; 2015 Jan; 24(1):206-12. PubMed ID: 25339418
[TBL] [Abstract][Full Text] [Related]
40. Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer.
Wei Z; Wang W; Shu Z; Zhou X; Zhang Y
Med Sci Monit; 2017 Jul; 23():3627-3634. PubMed ID: 28742791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
